Most people taking popular drugs like Ozempic and Wegovy to lose weight have shed significant pounds. But obesity experts say that roughly 20% of patients — as many as 1 in 5 — may not see robust ...

Antag Therapeutics thinks its glucose dependent insulinotropic polypeptide receptor (GIPR) antagonist could carve out a space ...

Last year’s study in the journal Obesity had revealed that of people prescribed weight-loss drugs, just 44 per cent were ...

Weight loss drugs such as Ozempic and Wegovy are increasingly popular among adults, who have flocked to the new medication as an alternative to the traditional - and often ineffective - advice to "eat ...

The American Diabetes Association (ADA) urged healthcare providers against prescribing non-FDA approved compounded GLP-1 and ...

Research reports that in the United States, the number of patients who underwent bariatric procedure decreased by 25%, while ...

Pfizer's Chris Boshoff outlines plans to prioritize high-return projects, with a focus on obesity, Oncology, and oral GLP-1 ...

The American Diabetes Association is advising doctors and patients not to use compounded GLP-1s due to uncertainty about their content, safety, ...

Researchers have developed and are testing a small, implanted gastric balloon that people can inflate or deflate to feel full ...

Is It Better To Shower In The Morning Or At Night? Well, It Depends.

Brand companies who own GLP-1 products have been pushing the Food and Drug Administration (FDA) to limit their compounding. On August 28, 2024, ...

The Biden administration is proposing Medicare and Medicaid coverage for GLP-1 RA obesity medications like semaglutide (Wegovy) and tirzepatide (Zepbound), challenging a two-decade-old law and facing ...